Windlas Biotech share news, announcements and annual reports
NSE: WINDLASBSE: 543329Pharmaceuticals & BiotechnologySmall Cap
Windlas Biotech Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2021 · Issue price ₹460
Last close ₹923.40up ₹34.70 (3.90%)BSE ₹923.40
Share price at the NSE close on 29 Oct 2026. Previous close ₹888.70.
29 Oct: open ₹899.70, high ₹936.40, low ₹887.00
52-week range of traded prices to 29 Oct 2026
₹697.40Low, 16 Mar 2026₹1,181.90High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,906 Cr1,237th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 28.69
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 3.28
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.68%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,08,21543.7% delivered
Windlas Biotech share news and announcements
322 announcements, routine notices left out, newest first. Page 5 of 7.
May 2023
5 May · Business
5 May · Results
3 May · Closure of Buy Back
Apr 2023
29 Apr · Analysts
28 Apr · Board meeting
Meeting on 5 May 2023: “WINDLAS BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 05-May-2023 to consider financial statements for the period ended March 2023, Financial results/Other business.”28 Apr · Updates
24 Apr · Analysts
Mar 2023
30 Mar · Analysts
9 Mar · Analysts
Feb 2023
22 Feb · Analysts
8 Feb · Business
8 Feb · Business
8 Feb · Results
8 Feb · Board meeting
2 Feb · Board meeting
Jan 2023
31 Jan · Analysts
30 Jan · Board meeting
3 Jan · Analysts
Dec 2022
20 Dec · Analysts
20 Dec · Analysts
5 Dec · Analysts
Nov 2022
30 Nov · Analysts
16 Nov · Related Party Transaction
9 Nov · General updates
8 Nov · General updates
8 Nov · Business
5 Nov · Analysts
Oct 2022
Sep 2022
22 Sep · Analysts
19 Sep · Meeting
13 Sep · Analysts
8 Sep · Analysts
1 Sep · Analysts
Aug 2022
26 Aug · General updates
26 Aug · Meeting